SeraCare Life Sciences, Inc. (NASDAQ: SRLS) today announced that the Company has launched a set of new products in its diagnostic controls and panels portfolio—the SeraCare HIV-1 Seroconversion Panels. Each of the six panels consists of a set of undiluted plasma samples from a single plasma donor collected over a period of time during the development of detectable specific antibodies to HIV in the blood, or seroconversion, and is highly characterized with enhanced product information. Extensively defined natural patient samples are vital for assay development and regulatory compliance. SeraCare's HIV seroconversion panels can be used by customers to accelerate development of new test methods, provide a common reference for assay comparison and troubleshoot existing assays.
“These latest new product offerings build on more than 20 years of SeraCare leadership in helping scientists develop diagnostic tools for HIV and support our continued future growth.”
"SeraCare's HIV product portfolio provides scientists with one of the industry's most comprehensive historical reference platforms to study this rapidly changing disease," said Susan Vogt, President and Chief Executive Officer. "These latest new product offerings build on more than 20 years of SeraCare leadership in helping scientists develop diagnostic tools for HIV and support our continued future growth."
SeraCare HIV-1 Seroconversion Panels are supplied with comprehensive test data vital for assay development and regulatory compliance, including results from twenty U.S. and international test methods for markers of HIV infection such as HIV RNA, 1st to 4th generation screening tests for HIV, confirmatory tests and a rapid discriminatory method. A seroconversion graph of critical data points is also included. The data for SeraCare's new HIV-1 Seroconversion Panels will be available at www.seracarepanels.com. The enhanced on-line data feature allows SeraCare to provide timely updates whenever new test data are available.
Common HIV drugs linked to reduced Alzheimer's disease risk